Kenya's Universal Corporation Limited (UCL) has been granted the rights to manufacture alimatavir, a new drug aimed at preventing HIV infection. The drug is designed to be taken once a month. Merck, also known as MSD, has granted seven companies worldwide, including three in Africa, the rights to produce alimatavir at a low cost. The companies will start marketing the drug after it has been tested and proven to be safe and effective in preventing HIV.
The three African companies granted the rights are UCL, Quality Chemical Industries Limited of Uganda, and Aspen Pharmacare of South Africa. This is the first time African companies have been included in a global initiative to produce a HIV prevention drug before the final stages of testing have been completed. Clinical trials for alimatavir are currently underway in Kenya, Uganda, and South Africa, involving young women and girls.
Although alimatavir has not yet been approved for use, its development has been hailed as a significant step forward in the fight against HIV. The drug's manufacturer, Merck, will not receive royalties from the African companies producing it. Merck has stated that once the drug is approved, it will be made available at a low cost, with the companies producing it working to scale up production.
The grant of rights to produce alimatavir has been welcomed by Kenyan President William Ruto, who stated that Africa has long borne a significant burden of disease, but has not produced many of the treatments and vaccines used to combat it. Ruto's comments were conveyed by Kenya's Health Secretary, Aden Duale, at a meeting on the sidelines of the United Nations General Assembly.
If approved, alimatavir could become the first once-a-month HIV prevention drug. The drug's development has been facilitated by a global initiative aimed at increasing access to HIV prevention treatments in low- and middle-income countries. A total of 129 countries will benefit from the agreement.
The production of alimatavir by African companies is seen as a major milestone in the fight against HIV in Africa. The region has been disproportionately affected by the disease, with many countries struggling to provide treatment and prevention services to those in need.
The clinical trials for alimatavir are ongoing, and the results are eagerly awaited. If the drug is proven to be safe and effective, it could provide a new tool in the fight against HIV, particularly for young women and girls who are disproportionately affected by the disease in Africa.
Key points
- Merck grants rights to produce alimatavir to seven companies worldwide, including three in Africa.
- Alimatavir is designed to be taken once a month to prevent HIV infection.
- The drug's production by African companies is seen as a significant step forward in the fight against HIV in the region.
